Sotoraxibu release date

Sotoracib (AMG510) is an anti-tumor targeted drug that targets the KRAS G12C mutation. Sotoracib is the world’s first targeted drug targeting the KRAS G12C mutation, and has a significant effect in the treatment of lung cancer.

Sotorasibu was approved for marketing in2021year5month28Nikkei USFDA. The original drug has European and American versions, but it is not currently available in China. Overseas pharmaceutical companies produce generic drugs of this drug. Sotorasibu produced by Bangladesh Everest Pharmaceuticals, Ziska Pharmaceuticals, Laos ASEAN, Lucius and other manufacturers has been put on the market. Sotoracib produced by Ziska Pharmaceuticals will be launched in 2022. Sotaracib produced by Everest Pharmaceuticals, ASEAN Pharmaceuticals, and Lucius Pharmaceuticals will be launched in 2023. Different countries, different pharmaceutical manufacturers, and different pricing. Patients can choose drug versions according to their own economic conditions.

Before taking sotoracib, tell your doctor if you are allergic to sotoracib, any other medicine, or any of the ingredients in sotoracib tablets. Tell your doctor about other prescription and over-the-counter drugs, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change your medication dosage or carefully monitor for side effects. If you are taking sotoracib and an antacid, take sotoracib 4 hours before or 10 hours after taking the antacid. Tell your doctor if you have or have ever had liver disease, or lung or respiratory disease other than lung cancer. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.